Akash Nahar

856 total citations
32 papers, 384 citations indexed

About

Akash Nahar is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Akash Nahar has authored 32 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Akash Nahar's work include Lymphoma Diagnosis and Treatment (21 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Treatments and Mutations (9 papers). Akash Nahar is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Lung Cancer Treatments and Mutations (9 papers). Akash Nahar collaborates with scholars based in United States, Italy and Australia. Akash Nahar's co-authors include Pier Luigi Zinzani, Philippe Armand, Craig H. Moskowitz, Vincent Ribrag, Nathalie A. Johnson, Arun Balakumaran, Eunhee Kim, Pauline Brice, Robert Chen and Daniel Molin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Akash Nahar

31 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akash Nahar United States	7	306	255	108	91	59	32	384
Florence Broussais‐Guillaumot France	9	153 0.5×	228 0.9×	55 0.5×	57 0.6×	95 1.6×	14	305
Federica Quirini Italy	11	179 0.6×	372 1.5×	115 1.1×	80 0.9×	116 2.0×	17	432
Antonella Anastasia Italy	10	161 0.5×	216 0.8×	40 0.4×	92 1.0×	78 1.3×	21	284
Anna Ruskova New Zealand	8	97 0.3×	184 0.7×	63 0.6×	86 0.9×	93 1.6×	15	282
Emanuela Anna Pesce Italy	6	169 0.6×	257 1.0×	69 0.6×	42 0.5×	66 1.1×	12	287
S. Wiedenmann Germany	8	182 0.6×	278 1.1×	43 0.4×	94 1.0×	94 1.6×	8	350
Hanne Kuitunen Finland	12	168 0.5×	270 1.1×	45 0.4×	92 1.0×	157 2.7×	45	380
Gaetana Capobianco Italy	10	134 0.4×	198 0.8×	42 0.4×	68 0.7×	90 1.5×	21	281
Youngil Koh South Korea	8	155 0.5×	209 0.8×	110 1.0×	38 0.4×	29 0.5×	19	274

Countries citing papers authored by Akash Nahar

Since Specialization

Citations

This map shows the geographic impact of Akash Nahar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akash Nahar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akash Nahar more than expected).

Fields of papers citing papers by Akash Nahar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akash Nahar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akash Nahar. The network helps show where Akash Nahar may publish in the future.

Co-authorship network of co-authors of Akash Nahar

This figure shows the co-authorship network connecting the top 25 collaborators of Akash Nahar. A scholar is included among the top collaborators of Akash Nahar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akash Nahar. Akash Nahar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Erba, Harry P., Sudhir Unni, Eva Westerberg, et al.. (2024). Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia. Blood. 144(Supplement 1). 1509–1509. 1 indexed citations

Nahar, Akash, et al.. (2023). Unfavorable Early-Stage Hodgkin Lymphoma: Assessment of Patient Characteristics in a Real-World Setting. Future Oncology. 19(18). 1249–1259. 2 indexed citations

Raut, Monika, et al.. (2022). Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin’s lymphoma. Future Oncology. 18(32). 3623–3636. 1 indexed citations

Advani, Ranjana H., Abraham Avigdor, Anna Sureda, et al.. (2022). Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study. Blood. 140(Supplement 1). 1759–1760. 3 indexed citations

Vinti, Luciana, Stephen Daw, Constantino Sábado, et al.. (2022). S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY. HemaSphere. 6. 105–106. 1 indexed citations

Johnson, Nathalie A., David Lavie, Peter Borchmann, et al.. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood. 140(Supplement 1). 6540–6542. 2 indexed citations

Winter, Jane N., Akash Nahar, Eunhee Kim, & Patricia Marinello. (2021). Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study. Blood. 138(Supplement 1). 1379–1379. 2 indexed citations

Zinzani, Pier Luigi, Radhakrishnan Ramchandren, Armando Santoro, et al.. (2021). Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances. 6(2). 590–599. 13 indexed citations

Laliberté, François, Monika Raut, Guillaume Germain, et al.. (2020). Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA. Targeted Oncology. 16(1). 85–94. 2 indexed citations

10.

Kuruvilla, John, Radhakrishnan Ramchandren, Armando Santoro, et al.. (2020). KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).. Journal of Clinical Oncology. 38(15_suppl). 8005–8005. 23 indexed citations

11.

Armand, Philippe, John Kuruvilla, Jean‐Marie Michot, et al.. (2020). KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Advances. 4(12). 2617–2622. 33 indexed citations

12.

Kuruvilla, John, Radhakrishnan Ramchandren, Armando Santoro, et al.. (2020). Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. Blood. 136(Supplement 1). 12–12. 2 indexed citations

13.

Mauz‐Koerholz, Christine, et al.. (2019). Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667. Annals of Oncology. 30. ix96–ix96. 2 indexed citations

14.

Gregory, Gareth P., Pier Luigi Zinzani, John Palcza, et al.. (2019). Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. Clinical Trials. CT106–CT106. 3 indexed citations

15.

Mauz‐Körholz, Christine, Kara M. Kelly, Frank G. Keller, et al.. (2018). KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.. Journal of Clinical Oncology. 36(15_suppl). TPS7583–TPS7583. 5 indexed citations

16.

Nahar, Akash, et al.. (2018). Prediction of Thyroid Malignancies by Thyroid Auto Antibodies.. PubMed. 27(3). 585–595. 4 indexed citations

17.

Moskowitz, Craig H., Robert W. Chen, Philippe Armand, et al.. (2017). Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification. Blood. 130. 4085–4085. 3 indexed citations

18.

Nahar, Akash, et al.. (2013). Factors Related To Dental Caries Among The Patients Attending At The Outpatient Department (OPD) Of Dhaka Dental College And Hospital. 3(1). 16–20. 2 indexed citations

19.

Nahar, Akash, et al.. (2011). Plasma Homocysteine Levels, Methylene Tetrahydrofolate Reductase Polymorphisms, and the Risk of Thromboembolism in Children. Journal of Pediatric Hematology/Oncology. 33(5). 330–333. 5 indexed citations

20.

Hussain, Mohammad Asif, et al.. (1970). Study on Life Style of the Patients of Rheumatic Fever Attending the National Centre for Control of Rheumatic Fever and Heart Diseases (NCCRF/HD) During the Year 1993 to 1996. Journal of Dhaka Medical College. 17(2). 56–58. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact